Literature DB >> 19574641

Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2.

Yang Liu1, Huihao Zhou, Juanjuan Zhu, Yongxiang Gao, Liwen Niu, Jing Liu, Maikun Teng.   

Abstract

ErbB2 is a transmembrane tyrosine kinase, the overexpression of which causes abnormality and disorder in cell signalling and leads to cell transformation. Previously, an anti-ErbB2 single-chain chimeric antibody chA21 that specifically inhibits the growth of ErbB2-overexpressing cancer cells in vitro and in vivo was developed. Here, an antibody-antigen complex consisting of the single-chain variable fragment (scFv) of chA21 and an N-terminal fragment (residues 1-192, named EP I) of the ErbB2 extracellular domain was crystallized using the sitting-drop vapour-diffusion method. An X-ray diffraction data set was collected to 2.45 A resolution from a single flash-cooled crystal; the crystal belonged to space group P2(1)2(1)2(1).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574641      PMCID: PMC2705636          DOI: 10.1107/S1744309109020107

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  18 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

2.  Development of herceptin.

Authors:  P Carter; B M Fendly; G D Lewis; M X Sliwkowski
Journal:  Breast Dis       Date:  2000

3.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors.

Authors:  Thomas P J Garrett; Neil M McKern; Meizhen Lou; Thomas C Elleman; Timothy E Adams; George O Lovrecz; Michael Kofler; Robert N Jorissen; Edouard C Nice; Antony W Burgess; Colin W Ward
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

4.  [Soluble expression and characterization of disulfide bond-rich subdomains of membrane protein p185 in Escherichia coli].

Authors:  Liang-Wei Li; Hai-Bo Liu; Si-Yi Hu; Dun Liang; Lian-Sheng Cheng; Jing Liu
Journal:  Sheng Wu Gong Cheng Xue Bao       Date:  2005-07

5.  Characterization and utilization of two novel anti-erbB-2 monoclonal antibodies in detection of soluble ErbB-2 for breast cancer prognosis.

Authors:  P Li; Y Li; J Y Li; J Liu
Journal:  Cancer Lett       Date:  2003-04-25       Impact factor: 8.679

6.  A survey of protein-protein complex crystallizations.

Authors:  Sergei Radaev; Sean Li; Peter D Sun
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2006-05-12

7.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

Review 8.  The ErbB receptors and their role in cancer progression.

Authors:  Thomas Holbro; Gianluca Civenni; Nancy E Hynes
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

Review 9.  Interaction of antibodies with ErbB receptor extracellular regions.

Authors:  Karl R Schmitz; Kathryn M Ferguson
Journal:  Exp Cell Res       Date:  2008-10-22       Impact factor: 3.905

Review 10.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  2 in total

1.  Structural insights into the down-regulation of overexpressed p185(her2/neu) protein of transformed cells by the antibody chA21.

Authors:  Huihao Zhou; Zhao Zha; Yang Liu; Hongtao Zhang; Juanjuan Zhu; Siyi Hu; Guodong Shen; Liansheng Cheng; Liwen Niu; Mark I Greene; Maikun Teng; Jing Liu
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

2.  Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft.

Authors:  Anli Zhang; Guodong Shen; Ting Zhao; Guihong Zhang; Jing Liu; Lihua Song; Wei Wei; Ling Bing; Zhengsheng Wu; Qiang Wu
Journal:  J Ovarian Res       Date:  2010-08-19       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.